Shares of Heat Biologics Inc. (HTBX) tumbled nearly 57% in extended trading on Wednesday, following disappointing results from its phase II study of bladder cancer cell vaccine HS-410 in the treatment of non-muscle invasive bladder cancer.
from RTT - Biotech http://ift.tt/2gKwa0r
via IFTTT
No comments:
Post a Comment